PRELIMINARY ANALYSIS FOR THE USE OF BIOLOGICALS IN THE TREATMENT OF RHEUMATOID ARTHRITIS

Detalhes bibliográficos
Autor(a) principal: Silva , Alexia Ribeiro
Data de Publicação: 2023
Outros Autores: Costa , Guilherme Spezia Dalla, Kahlow , Barbara Stadler, Skare, Thelma
Tipo de documento: preprint
Idioma: por
Título da fonte: SciELO Preprints
Texto Completo: https://preprints.scielo.org/index.php/scielo/preprint/view/6548
Resumo: Introduction: Rheumatoid arthritis (RA) is treated with conventional and biological disease-modifying drugs (DMARDs). Objectives: To compare the survival of biological drugs used for the treatment of RA patients. Methods: Retrospective study of medical records of patients who used biological medication for the treatment of RA from January 2020 to January 2022 and this was suspended. Data on the causes of withdrawal, duration of use, epidemiological, clinical and comorbid data were collected. Results: The main reason for discontinuity was failure followed by side effects. Infliximab and adalimumab had the highest survival. BMI (body mass index) and smoking, sex and age did not interfere in this survival. Conclusion: Failure is the most common cause of biological discontinuity. Among the factors studied (smoking, BMI, age and gender) it was not possible to identify a variable that was associated with failure.
id SCI-1_8a62a53586404c4e0c3e72d0987ea8d0
oai_identifier_str oai:ops.preprints.scielo.org:preprint/6548
network_acronym_str SCI-1
network_name_str SciELO Preprints
repository_id_str
spelling PRELIMINARY ANALYSIS FOR THE USE OF BIOLOGICALS IN THE TREATMENT OF RHEUMATOID ARTHRITISANÁLISE PRELIMINAR DO USO DE BIOLÓGICOS NO TRATAMENTO DA ARTRITE REUMATOIDEArtrite reumatoideTratamentoBiológicosRheumatoid arthritisTreatmentBiological drugsIntroduction: Rheumatoid arthritis (RA) is treated with conventional and biological disease-modifying drugs (DMARDs). Objectives: To compare the survival of biological drugs used for the treatment of RA patients. Methods: Retrospective study of medical records of patients who used biological medication for the treatment of RA from January 2020 to January 2022 and this was suspended. Data on the causes of withdrawal, duration of use, epidemiological, clinical and comorbid data were collected. Results: The main reason for discontinuity was failure followed by side effects. Infliximab and adalimumab had the highest survival. BMI (body mass index) and smoking, sex and age did not interfere in this survival. Conclusion: Failure is the most common cause of biological discontinuity. Among the factors studied (smoking, BMI, age and gender) it was not possible to identify a variable that was associated with failure.Introdução: A artrite reumatoide (AR) é tratada com drogas modificadoras da doença (DMARDs) convencionais e biológicas. Objetivos: Comparar a sobrevida de medicamentos biológicos utilizados para o tratamento de pacientes com AR. Método: Estudo retrospectivo de prontuários de pacientes que utilizaram medicamento biológico para tratamento de AR de janeiro de 2020 a janeiro de 2022 e este foi suspenso. Dados acerca das causas de retirada, tempo de uso, dados epidemiológicos, clínicos e de comorbidades foram coletados. Resultados: O principal motivo da descontinuidade foi a falha seguida por efeitos colaterais. Infliximabe e adalimumabe foram os que apresentaram maior sobrevida. IMC (índice de massa corporal) e o tabagismo, sexo e idade não mostraram interferência nesta sobrevida Conclusão: Falha é a causa mais comum de descontinuidade dos biológicos. Dentre os fatores estudados (fumo, IMC, idade e sexo) não foi possível identificar variável que se associasse com falha.SciELO PreprintsSciELO PreprintsSciELO Preprints2023-08-02info:eu-repo/semantics/preprintinfo:eu-repo/semantics/publishedVersionapplication/pdfhttps://preprints.scielo.org/index.php/scielo/preprint/view/654810.1590/SciELOPreprints.6548porhttps://preprints.scielo.org/index.php/scielo/article/view/6548/12442Copyright (c) 2023 Alexia Ribeiro Silva , Guilherme Spezia Dalla Costa , Barbara Stadler Kahlow , Thelma Larocca Skarehttps://creativecommons.org/licenses/by/4.0info:eu-repo/semantics/openAccessSilva , Alexia RibeiroCosta , Guilherme Spezia DallaKahlow , Barbara StadlerSkare, Thelmareponame:SciELO Preprintsinstname:Scientific Electronic Library Online (SCIELO)instacron:SCI2023-08-01T20:12:01Zoai:ops.preprints.scielo.org:preprint/6548Servidor de preprintshttps://preprints.scielo.org/index.php/scieloONGhttps://preprints.scielo.org/index.php/scielo/oaiscielo.submission@scielo.orgopendoar:2023-08-01T20:12:01SciELO Preprints - Scientific Electronic Library Online (SCIELO)false
dc.title.none.fl_str_mv PRELIMINARY ANALYSIS FOR THE USE OF BIOLOGICALS IN THE TREATMENT OF RHEUMATOID ARTHRITIS
ANÁLISE PRELIMINAR DO USO DE BIOLÓGICOS NO TRATAMENTO DA ARTRITE REUMATOIDE
title PRELIMINARY ANALYSIS FOR THE USE OF BIOLOGICALS IN THE TREATMENT OF RHEUMATOID ARTHRITIS
spellingShingle PRELIMINARY ANALYSIS FOR THE USE OF BIOLOGICALS IN THE TREATMENT OF RHEUMATOID ARTHRITIS
Silva , Alexia Ribeiro
Artrite reumatoide
Tratamento
Biológicos
Rheumatoid arthritis
Treatment
Biological drugs
title_short PRELIMINARY ANALYSIS FOR THE USE OF BIOLOGICALS IN THE TREATMENT OF RHEUMATOID ARTHRITIS
title_full PRELIMINARY ANALYSIS FOR THE USE OF BIOLOGICALS IN THE TREATMENT OF RHEUMATOID ARTHRITIS
title_fullStr PRELIMINARY ANALYSIS FOR THE USE OF BIOLOGICALS IN THE TREATMENT OF RHEUMATOID ARTHRITIS
title_full_unstemmed PRELIMINARY ANALYSIS FOR THE USE OF BIOLOGICALS IN THE TREATMENT OF RHEUMATOID ARTHRITIS
title_sort PRELIMINARY ANALYSIS FOR THE USE OF BIOLOGICALS IN THE TREATMENT OF RHEUMATOID ARTHRITIS
author Silva , Alexia Ribeiro
author_facet Silva , Alexia Ribeiro
Costa , Guilherme Spezia Dalla
Kahlow , Barbara Stadler
Skare, Thelma
author_role author
author2 Costa , Guilherme Spezia Dalla
Kahlow , Barbara Stadler
Skare, Thelma
author2_role author
author
author
dc.contributor.author.fl_str_mv Silva , Alexia Ribeiro
Costa , Guilherme Spezia Dalla
Kahlow , Barbara Stadler
Skare, Thelma
dc.subject.por.fl_str_mv Artrite reumatoide
Tratamento
Biológicos
Rheumatoid arthritis
Treatment
Biological drugs
topic Artrite reumatoide
Tratamento
Biológicos
Rheumatoid arthritis
Treatment
Biological drugs
description Introduction: Rheumatoid arthritis (RA) is treated with conventional and biological disease-modifying drugs (DMARDs). Objectives: To compare the survival of biological drugs used for the treatment of RA patients. Methods: Retrospective study of medical records of patients who used biological medication for the treatment of RA from January 2020 to January 2022 and this was suspended. Data on the causes of withdrawal, duration of use, epidemiological, clinical and comorbid data were collected. Results: The main reason for discontinuity was failure followed by side effects. Infliximab and adalimumab had the highest survival. BMI (body mass index) and smoking, sex and age did not interfere in this survival. Conclusion: Failure is the most common cause of biological discontinuity. Among the factors studied (smoking, BMI, age and gender) it was not possible to identify a variable that was associated with failure.
publishDate 2023
dc.date.none.fl_str_mv 2023-08-02
dc.type.driver.fl_str_mv info:eu-repo/semantics/preprint
info:eu-repo/semantics/publishedVersion
format preprint
status_str publishedVersion
dc.identifier.uri.fl_str_mv https://preprints.scielo.org/index.php/scielo/preprint/view/6548
10.1590/SciELOPreprints.6548
url https://preprints.scielo.org/index.php/scielo/preprint/view/6548
identifier_str_mv 10.1590/SciELOPreprints.6548
dc.language.iso.fl_str_mv por
language por
dc.relation.none.fl_str_mv https://preprints.scielo.org/index.php/scielo/article/view/6548/12442
dc.rights.driver.fl_str_mv https://creativecommons.org/licenses/by/4.0
info:eu-repo/semantics/openAccess
rights_invalid_str_mv https://creativecommons.org/licenses/by/4.0
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
dc.publisher.none.fl_str_mv SciELO Preprints
SciELO Preprints
SciELO Preprints
publisher.none.fl_str_mv SciELO Preprints
SciELO Preprints
SciELO Preprints
dc.source.none.fl_str_mv reponame:SciELO Preprints
instname:Scientific Electronic Library Online (SCIELO)
instacron:SCI
instname_str Scientific Electronic Library Online (SCIELO)
instacron_str SCI
institution SCI
reponame_str SciELO Preprints
collection SciELO Preprints
repository.name.fl_str_mv SciELO Preprints - Scientific Electronic Library Online (SCIELO)
repository.mail.fl_str_mv scielo.submission@scielo.org
_version_ 1797047812379115520

Registros relacionados